Xalkori is prescribed by oncologists for the treatment of the following conditions: 🔹 ALK-positive NSCLC: Advanced or metastatic non-small cell lung cancer expressing anaplastic lymphoma kinase (ALK). 🔹 ROS1-positive NSCLC: Metastatic non-small cell lung cancer with a mutation in the ROS1 gene.

Dosage and administration

Sales Form: 1 pack contains 60 capsules of 250 mg.⚠️ INSTRUCTIONS FOR USE: Dosage Regimen: The standard recommended dose is 250 mg twice daily (morning and evening). Method: Capsules are taken orally whole. They should not be crushed or dissolved. They can be taken with or without food. Missed Dose: If the next dose is due in less than 6 hours, the missed dose should not be taken. Important: Avoid grapefruit and grapefruit juice during therapy, as they can alter the drug's concentration in the blood. Storage: Store in the original packaging at a temperature not exceeding 30°C.

⛔ Hypersensitivity: Allergy to crizotinib or any excipients. ⛔ Pregnancy and Lactation: The drug is highly toxic to the fetus. Contraindicated for pregnant women. Breastfeeding must be discontinued during therapy. ⛔ Hepatic and Renal Impairment: Severe renal or hepatic insufficiency requires special caution and dose adjustment. ⛔ Heart Disease: QT interval prolongation, severe bradycardia (requires continuous ECG monitoring). ⛔ Age: Safety for use in children and adolescents under 18 years of age has not been established.

Treatment with Xalkori may be accompanied by side effects that require monitoring by the attending physician: 👁️ Vision: Visual disturbances (double vision, light flashes, "film" before the eyes) — often observed at the beginning of therapy. 🤢 GI Tract: Nausea, diarrhea, vomiting, constipation. 🧪 Liver: Increased levels of liver enzymes (ALT, AST). Regular blood tests are required. 🫁 Lungs: In rare cases, interstitial pneumonitis may occur (if shortness of breath or cough develops, consult a doctor immediately). 🤕 General: Edema of the extremities, fatigue, dizziness. ⚠️ Important: If severe abdominal pain, yellowing of the skin, or a sudden change in heart rhythm occurs, consult an oncologist immediately.

Xalkori — Crizotinib 250 mg, 60 pcs, Pfizer

100% original product

Active ingredient

Crizotinib

Manufacturer

Pfizer

Dosage 250 mg

Dosage form Capsules

Capsules per pack 60

Xalkori — Crizotinib 250 mg (60 Capsules)

Name: Xalkori
Brand: Pfizer
SKU: PROD-279
Price: 57367 UAH
Availability: InStock

57367₴ ~~61779₴~~ -7% On order · from 7 days

Xalkori (Crizotinib) is an innovative antineoplastic medication belonging to the group of protein tyrosine kinase inhibitors. It is designed for targeted therapy of specific forms of non-small cell lung cancer (NSCLC). The active substance — crizotinib — blocks the activity of ALK, ROS1, and MET receptors, which stimulate the growth and division of malignant cells. As a result, the drug effectively slows disease progression and contributes to tumor shrinkage.

Manufacturer: Pfizer. Xalkori was the first drug to change the standard of care for patients with ALK-positive status, providing significantly higher survival rates and quality of life compared to traditional chemotherapy.

Key Features:

✅ Targeted Action: Specifically attacks cancer cells with specific genetic mutations (ALK or ROS1), with minimal damage to healthy tissues.
✅ Clinical Efficacy: Proven significant increase in progression-free survival.
✅ Convenience: Oral administration allows patients to undergo treatment at home.

Xalkori is prescribed by oncologists for the treatment of the following conditions:

🔹 ALK-positive NSCLC: Advanced or metastatic non-small cell lung cancer expressing anaplastic lymphoma kinase (ALK).
🔹 ROS1-positive NSCLC: Metastatic non-small cell lung cancer with a mutation in the ROS1 gene.

Sales Form: 1 pack contains 60 capsules of 250 mg.

⚠️ INSTRUCTIONS FOR USE:

Dosage Regimen: The standard recommended dose is 250 mg twice daily (morning and evening).
Method: Capsules are taken orally whole. They should not be crushed or dissolved. They can be taken with or without food.
Missed Dose: If the next dose is due in less than 6 hours, the missed dose should not be taken.
Important: Avoid grapefruit and grapefruit juice during therapy, as they can alter the drug's concentration in the blood.
Storage: Store in the original packaging at a temperature not exceeding 30°C.

⛔ Hypersensitivity: Allergy to crizotinib or any excipients.
⛔ Pregnancy and Lactation: The drug is highly toxic to the fetus. Contraindicated for pregnant women. Breastfeeding must be discontinued during therapy.
⛔ Hepatic and Renal Impairment: Severe renal or hepatic insufficiency requires special caution and dose adjustment.
⛔ Heart Disease: QT interval prolongation, severe bradycardia (requires continuous ECG monitoring).
⛔ Age: Safety for use in children and adolescents under 18 years of age has not been established.

Treatment with Xalkori may be accompanied by side effects that require monitoring by the attending physician:

👁️ Vision: Visual disturbances (double vision, light flashes, "film" before the eyes) — often observed at the beginning of therapy.
🤢 GI Tract: Nausea, diarrhea, vomiting, constipation.
🧪 Liver: Increased levels of liver enzymes (ALT, AST). Regular blood tests are required.
🫁 Lungs: In rare cases, interstitial pneumonitis may occur (if shortness of breath or cough develops, consult a doctor immediately).
🤕 General: Edema of the extremities, fatigue, dizziness.
⚠️ Important: If severe abdominal pain, yellowing of the skin, or a sudden change in heart rhythm occurs, consult an oncologist immediately.